Xinhua, Beijing, March 9 (Wu Qilong) During the 2023 National People's Congress and the National People's Congress, Lu Qingguo, the representative of the National People's Congress and the chairman and general manager of Chenguang Biotechnology Group Co., Ltd., made suggestions and suggestions on the quality of traditional Chinese medicine and the revision of the pharmacopoeia.

Lu Qingguo, NPC Representative, Chairman and General Manager of Chenguang Biology

According to Lu Qingguo, a representative of the National People's Congress and chairman and general manager of Chenguang Biology, there is an urgent need for standardization of traditional Chinese medicine and patent medicines to improve the quality and efficacy of traditional Chinese medicine.

In order to ensure the quality of traditional Chinese medicine, he believes that China currently has modern testing conditions that allow for analysis of the main components of traditional Chinese medicine and strict quantitative standards.

In terms of the pharmacopoeia, the representative of Lu Qingguo proposed to focus on initiating the revision of the pharmacopoeia. For the effective ingredient content standards of Chinese medicinal materials, several representative main ingredients can be selected, and the indicators of medium and above quality medicinal materials from genuine medicinal materials production areas can be used as a reference to improve the existing pharmacopoeia standards, gradually increasing and improving the ingredient content indicators.

He suggested that the implementation of the new pharmacopoeia standards could establish a transitional period of several years to gradually guide the cultivation of medicinal materials to develop into advantageous production areas, continuously improve the quality and effective ingredient content of traditional Chinese medicine, ensure the efficacy of traditional Chinese medicine, and assist the high-quality development of the traditional Chinese medicine industry.